Form 4 for XFOR X4 Pharmaceuticals, Inc
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001628280-23-003759 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-15 | 2023-02-13 | XFOR | Taveras Arthur | CSO | S - Sale | $0.93 | -928 | 103.2K | -0.9% | -$863.04 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | S | D | 928 | $0.93 | 103,179 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Of the shares of common stock reported, 99,679 shares represent restricted stock units. |